Hexarelin

Most growth hormone secretagogues are judged solely by how much GH they release. Hexarelin breaks that mold. Research suggests this synthetic hexapeptide triggers growth hormone release like its peers, but also binds to a cardiac receptor — CD36 — that ghrelin itself does not activate [1] PMID: 10465272 . This distinction matters: hexarelin's heart-protective effects operate through a completely GH-independent pathway.

Derived from GHRP-6 GHRP-6 growth hormone secretagogue (GHS) / ghrelin receptor agonist Ghrelin mimetic hexapeptide — strongest appetite stimulation among GHRPs with a single amino acid modification (a 2-methyl-tryptophan substitution at position 2), hexarelin gained attention not only for its GH-releasing potency but for cardioprotective properties that researchers did not initially expect. The peptide's binding affinity for CD36 — a scavenger receptor found on cardiomyocytes — opened a separate line of investigation into cardiovascular protection.

Preclinical data indicate effects spanning muscle growth, fat metabolism, cardiac function, and anti-inflammatory activity [PMID: 7910650, 10465272, 12379504, 25645463]. The combination of GH-secretagogue activity and direct cardiac receptor engagement makes hexarelin a compound of genuine dual-pathway research interest.

II. What is this compound?

Hexarelin (also known as Examorelin) is a synthetic hexapeptide composed of six amino acids in the sequence His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2, with a molecular weight of 887 Da and the molecular formula C47H58N12O6.

The peptide was developed as a structural analog of GHRP-6 GHRP-6 growth hormone secretagogue (GHS) / ghrelin receptor agonist Ghrelin mimetic hexapeptide — strongest appetite stimulation among GHRPs , the first-generation growth hormone-releasing peptide. The key modification — replacement of the native tryptophan at position 2 with a D-2-methyl-tryptophan residue — increased metabolic stability and receptor binding affinity. This single substitution gave hexarelin a half-life of approximately 55 to 71 minutes in human intravenous studies, longer than its parent compound.

What distinguishes hexarelin from other GHS compounds in the research literature is its dual receptor profile. Like all growth hormone secretagogues, it activates the ghrelin receptor (GHSR-1a) on pituitary somatotrophs to trigger growth hormone release [2] PMID: 7957536 . But hexarelin also binds to CD36, a class B scavenger receptor expressed on cardiomyocytes and other non-endocrine tissues [3] PMID: 10465272 . Ghrelin — the body's endogenous GHSR-1a ligand — does not bind CD36 in these tissues. This makes hexarelin pharmacologically distinct from both ghrelin and from other synthetic secretagogues.

The peptide is administered via subcutaneous, intramuscular, or intravenous injection in research settings. Its relatively short half-life means dosing frequency must account for rapid clearance, though this has not been a barrier in either preclinical animal studies or the limited human phase I data available [4] PMID: 7957536 .

III. How it works

Hexarelin operates through two distinct receptor systems — and this dual mechanism is what makes it a subject of active research interest.

The ghrelin receptor pathway is shared with other GHS compounds. When hexarelin binds GHSR-1a on pituitary somatotrophs, it activates G-alpha-q/11 and G-alpha-i/o signaling proteins, which trigger phospholipase C (PLC), increase intracellular calcium, and prompt the release of stored growth hormone [PMID: 7910650, 7957536]. A dose-response study in healthy human volunteers confirmed that intravenous hexarelin at doses of 0.5 to 2 mcg/kg produces a significant, dose-dependent rise in circulating GH levels [5] PMID: 7957536 .

The CD36 pathway is unique to hexarelin among well-characterized growth hormone secretagogues. CD36 is a scavenger receptor found on cardiomyocytes, macrophages, and vascular endothelium. Research shows that hexarelin's binding to CD36 on heart muscle cells activates protein kinase C (PKC) signaling and enhances L-type calcium current, producing a positive inotropic effect — increased contractile force — that operates independently of growth hormone [6] PMID: 10465272 .

This GH-independent cardioprotection is the most researched aspect of hexarelin's mechanism. Studies demonstrate that the peptide protects cardiomyocytes from apoptosis induced by angiotensin II, doxorubicin toxicity, and ischemia-reperfusion injury [PMC4178518]. It also reduces cardiac fibrosis by limiting collagen deposition and inhibiting fibroblast proliferation. In atherosclerosis models, hexarelin suppressed plaque formation and improved the HDL-to-LDL ratio [PMC4178518]. These cardiac effects are not secondary to GH elevation — they occur through direct receptor engagement in cardiac tissue.

The question researchers are still working to answer: how do these two pathways interact when both are active simultaneously? The GH axis and the CD36 signaling cascade may produce synergistic, additive, or independent effects depending on tissue context and dosing.

• GHSR-1a (ghrelin receptor) agonism - stimulates GH release from pituitary somatotrophs via G-alpha-q/11 and G-alpha-i/o, PLC, and Ca2+ cascade
  PMID 7910650PMID 7957536
• CD36 cardiac receptor binding - unique to hexarelin, mediates cardioprotective effects independent of growth hormone
  PMID 10465272PMID PMC4178518
• Positive inotropic effect via PKC signaling and L-type Ca2+ current enhancement
  PMID 10465272
• Anti-apoptotic effects in cardiomyocytes - protects against angiotensin II, doxorubicin, and ischemia-reperfusion injury
  PMID PMC4178518
• Anti-fibrotic activity - reduces collagen deposition and inhibits cardiac fibroblast proliferation
  PMID PMC4178518
• Anti-atherosclerotic effects - suppresses plaque formation, improves HDL/LDL ratio
  PMID PMC4178518

IV. Research Findings

Preclinical research suggests that hexarelin may support muscle growth through its growth hormone-releasing activity. In infant and adult rat models, hexarelin administration stimulated significant GH release, with downstream effects on protein synthesis and lean tissue accretion [7] PMID: 7910650 . Growth hormone is a well-established regulator of anabolic processes — it promotes nitrogen retention, increases protein synthesis rates, and stimulates skeletal muscle cell proliferation. However, the evidence for hexarelin's muscle-building effects remains preclinical, and no controlled human trials have validated these outcomes.

The cardiovascular effects represent hexarelin's most distinctive research profile. Unlike other GHS compounds whose cardiac effects are secondary to GH elevation, hexarelin's cardioprotective activity operates through direct CD36 binding [8] PMID: 10465272 . Studies in post-myocardial infarction models showed that hexarelin improved cardiac function — increased ejection fraction, reduced scar tissue, and limited adverse remodeling [9] PMID: 10614623 . The peptide also demonstrated anti-apoptotic, anti-fibrotic, and anti-atherosclerotic properties in cardiac tissue [PMC4178518]. These effects are GH-independent, meaning they persist even when the GH axis is blocked.

On body composition, research indicates potential effects on fat metabolism. Growth hormone influences lipolysis — the breakdown of stored triglycerides — and elevates metabolic rate [10] PMID: 12379504 . Animal studies suggest hexarelin may promote fat oxidation, though the magnitude and consistency of this effect require further investigation. The anti-inflammatory properties documented in preclinical research add another layer of interest: reduced systemic inflammation may support metabolic health beyond direct lipolytic effects [11] PMID: 25645463 .

Sleep quality is occasionally mentioned in anecdotal reports, likely linked to growth hormone's natural peak during deep sleep phases. No peer-reviewed studies have systematically examined hexarelin's effect on sleep architecture. These reports cannot be treated as evidence without controlled investigation.

• muscle-growth preclinical
  PMID 7910650
• cardiovascular-health preclinical
  PMID 10465272PMID 10614623PMID PMC4178518
• fat-loss preclinical
  PMID 12379504
• anti-inflammatory preclinical
  PMID 25645463

V. Dosage Context Explained

Dosage information for hexarelin comes from three sources: human phase I intravenous studies, anecdotal reports of self-administered subcutaneous use, and preclinical animal research. Each source has significant limitations.

The most rigorous data come from a dose-response study in healthy human volunteers [12] PMID: 7957536 . Intravenous bolus doses of 0.5, 1, and 2 mcg/kg produced a clear, dose-dependent increase in circulating growth hormone, with the 2 mcg/kg dose producing the largest GH spike. This study established that hexarelin is active in humans at low microgram-per-kilogram doses, but it did not examine repeated dosing, long-term effects, or subcutaneous administration.

Anecdotal reports from informal human use describe subcutaneous doses of 200 mcg per injection, administered one to three times daily. These figures lack clinical validation and do not represent established protocols. The short half-life (~55-71 minutes) means the compound clears rapidly, which has practical implications for dosing frequency in research design but does not constitute clinical guidance.

Animal studies have used doses in the range of 100 to 300 mcg/kg/day administered subcutaneously [13] PMID: 7910650 . Direct extrapolation from animal to human dosing involves substantial uncertainty due to differences in pharmacokinetics, receptor density, and metabolic rate between species.

Researchers designing protocols with hexarelin must establish dosing parameters based on their specific study designs, institutional requirements, and available literature while acknowledging the limited and experimental nature of available dosage information.

• Administration Routes

  subcutaneous

  Range

  200 mcg per injection, 1-3x daily

  anecdotal human use

• Administration Routes

  intravenous

  Range

  0.5, 1, 2 mcg/kg bolus

  human phase I dose-response study

  PMID 7957536
• Administration Routes

  subcutaneous

  Range

  100-300 mcg/kg/day

  animal studies

  PMID 7910650

VI. Side Effects: Research Context

The side effect profile reported for hexarelin is derived primarily from anecdotal accounts, limited human phase I data, and preclinical observations rather than controlled clinical trials with systematic safety monitoring.

The most commonly reported effect is a transient increase in appetite, which aligns with hexarelin's mechanism of action at the ghrelin receptor — the same receptor the body uses for hunger signaling [14] PMID: 7957536 . This effect is expected and mechanistically consistent. Mild headache and transient flushing at the injection site have also been reported anecdotally, as has water retention at higher doses. The water retention may relate to growth hormone's known effects on sodium retention and fluid balance.

Theoretical contraindications include active malignancy, given growth hormone's role in cellular proliferation, and conditions of growth hormone excess such as acromegaly or gigantism. A consideration unique to hexarelin is its CD36 binding: while the cardiac effects of CD36 engagement appear protective in preclinical models, the long-term consequences of chronic CD36 modulation in human cardiac tissue are unknown.

Beyond these reported effects and theoretical concerns, the long-term safety profile in humans remains entirely undocumented. The absence of systematic safety data is not evidence of safety — it is evidence of insufficient investigation. This underscores the importance of treating hexarelin strictly as a research compound.

• transient increase in appetite (ghrelin receptor activation)
• mild headache (anecdotal)
• water retention at high doses (anecdotal)
• transient flushing post-injection (anecdotal)

VII. Frequently Asked Questions